Biosystems International announced this week that it is partnering with biopharmaceutical firm Pharnext on a six-year project to develop diagnostics and therapeutics for Alzheimer's disease funded by €10.4 million ($14.2 million) from the French innovation agency OSEO.

The collaboration calls for the companies to develop a prototype blood-based protein biomarker diagnostic for Alzheimer's disease as well as a therapeutic for the disease and a companion test for monitoring the drug's effectiveness and stratifying patient populations by their response.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.